Journal of Experimental & Clinical Cancer Research (May 2024)

Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics

  • Xiaohan Shi,
  • Shiwei Guo,
  • Qiaonan Duan,
  • Wei Zhang,
  • Suizhi Gao,
  • Wei Jing,
  • Guojuan Jiang,
  • Xiangyu Kong,
  • Penghao Li,
  • Yikai Li,
  • Chuanqi Teng,
  • Xiaoya Xu,
  • Sheng Chen,
  • Baoning Nian,
  • Zhikuan Li,
  • Chaoliang Zhong,
  • Xiaolu Yang,
  • Guangyu Zhu,
  • Yiqi Du,
  • Dadong Zhang,
  • Gang Jin

DOI
https://doi.org/10.1186/s13046-024-03067-y
Journal volume & issue
Vol. 43, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Plasma cell-free DNA (cfDNA) fragmentomics has demonstrated significant differentiation power between cancer patients and healthy individuals, but little is known in pancreatic and biliary tract cancers. The aim of this study is to characterize the cfDNA fragmentomics in biliopancreatic cancers and develop an accurate method for cancer detection. Methods One hundred forty-seven patients with biliopancreatic cancers and 71 non-cancer volunteers were enrolled, including 55 patients with cholangiocarcinoma, 30 with gallbladder cancer, and 62 with pancreatic cancer. Low-coverage whole-genome sequencing (median coverage: 2.9 ×) was performed on plasma cfDNA. Three cfDNA fragmentomic features, including fragment size, end motif and nucleosome footprint, were subjected to construct a stacked machine learning model for cancer detection. Integration of carbohydrate antigen 19–9 (CA19-9) was explored to improve model performance. Results The stacked model presented robust performance for cancer detection (area under curve (AUC) of 0.978 in the training cohort, and AUC of 0.941 in the validation cohort), and remained consistent even when using extremely low-coverage sequencing depth of 0.5 × (AUC: 0.905). Besides, our method could also help differentiate biliopancreatic cancer subtypes. By integrating the stacked model and CA19-9 to generate the final detection model, a high accuracy in distinguishing biliopancreatic cancers from non-cancer samples with an AUC of 0.995 was achieved. Conclusions Our model demonstrated ultrasensitivity of plasma cfDNA fragementomics in detecting biliopancreatic cancers, fulfilling the unmet accuracy of widely-used serum biomarker CA19-9, and provided an affordable way for accurate noninvasive biliopancreatic cancer screening in clinical practice.

Keywords